Multi-target small molecular tyrosine kinase inhibitors (TKI; mainly targeting VEGFR, FGFR, KIT, etc.)have been developed and approved for refractory STS in multiple regions worldwide; examples include pazopanib, regorafenib, and anlotinib. The gene discussed is KDR; the disease is telomere syndrome.